ZNF410

Across TCGA pan-cancer cohorts, ZNF410 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF410 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ZNF410 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF410 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, LIHC, and THCA are the cancer types where ZNF410 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.096	0.496	.004	9	view →
LIHC	DFS	Median	All	0.014	0.527	<.001	9	view →
THCA	OS	Median	All	0.277	0.954	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →
UCEC	DFS	Median	All	0.953	0.629	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF410–CHOL (DFS)

Open the CHOL breakdown →